Literature DB >> 23809691

The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners.

Rossella E Nappi1, Sheryl Kingsberg, Ricardo Maamari, James Simon.   

Abstract

INTRODUCTION: Postmenopausal vaginal atrophy (VA) is a chronic condition with symptoms that include vaginal dryness, soreness, itching, burning, and dyspareunia. AIM: The CLarifying Vaginal Atrophy's Impact On SEx and Relationships survey evaluated the impact of VA on the physical and emotional aspects of sexual relationships between postmenopausal women and their male partners.
METHODS: Four thousand one hundred females and 4,100 males representing the United Kingdom, Finland, Norway, Sweden, Denmark, Italy, France, Canada, and the United States were surveyed. Assessments included: (i) talking about VA and its symptoms; (ii) the impact of VA on intimacy, relationships, and women's self-esteem; (iii) talking about VA and erectile dysfunction (ED); and (iv) the impact of local estrogen therapy (LET) on intimacy and relationships. MAIN OUTCOME MEASURES: Descriptive data on the impact of VA.
RESULTS: Twenty-eight percent of women did not tell their partners when they first encountered vaginal discomfort, mainly because they felt "it was just a natural part of growing older" (52%) or because of "embarrassment" (21%). Eighty-two percent of males wanted their partner to share their experiences with VA; males were also more comfortable discussing VA than females (68% vs. 58%, respectively). Having sex less often (women: 58%, men: 61%), less satisfying sex (women: 49%, men: 28%), and putting off having sex (women: 35%, men: 14%) were the main effects of VA. Intimacy avoidance was attributed to painful sex (women: 55%, men: 61%) and women's reduced sexual desire (women: 46%, men: 43%). Discussions about vaginal discomfort and ED were generally limited to partners and healthcare providers (HCPs). LET use resulted in less painful sex (women: 62%, men: 59%) and more satisfying sex (women: 47%, men: 49%).
CONCLUSIONS: VA has an adverse emotional and physical impact on postmenopausal women and their partners. These findings may encourage more open communication about VA between couples and their HCPs.
© 2013 International Society for Sexual Medicine.

Entities:  

Keywords:  Atrophy; Discomfort; Local Estrogen Therapy; Male Partner; Postmenopausal; Vaginal Dryness

Mesh:

Year:  2013        PMID: 23809691     DOI: 10.1111/jsm.12235

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  15 in total

1.  Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?

Authors:  Eleni Pitsouni; Themos Grigoriadis; Matthew Falagas; Angeliki Tsiveleka; Stefano Salvatore; Stavros Athanasiou
Journal:  Lasers Med Sci       Date:  2017-08-02       Impact factor: 3.161

2.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

3.  Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.

Authors:  Leslie R Schover; George P Baum; Lisa A Fuson; Abenaa Brewster; Amal Melhem-Bertrandt
Journal:  J Sex Med       Date:  2014-08-21       Impact factor: 3.802

4.  Sexual health needs and educational intervention preferences for women with cancer.

Authors:  Cara Stabile; Shari Goldfarb; Raymond E Baser; Deborah J Goldfrank; Nadeem R Abu-Rustum; Richard R Barakat; Maura N Dickler; Jeanne Carter
Journal:  Breast Cancer Res Treat       Date:  2017-05-25       Impact factor: 4.872

Review 5.  The role of the sexual partner in managing erectile dysfunction.

Authors:  Hongjun Li; Tiejun Gao; Run Wang
Journal:  Nat Rev Urol       Date:  2016-02-02       Impact factor: 14.432

Review 6.  The Recent Review of the Genitourinary Syndrome of Menopause.

Authors:  Hyun-Kyung Kim; So-Yeon Kang; Youn-Jee Chung; Jang-Heub Kim; Mee-Ran Kim
Journal:  J Menopausal Med       Date:  2015-08-28

7.  WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.

Authors:  Sheryl A Kingsberg; Lisa Larkin; Michael Krychman; Sharon J Parish; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-02       Impact factor: 2.953

8.  Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study.

Authors:  W H Utian; R Maamari
Journal:  Climacteric       Date:  2013-11-05       Impact factor: 3.005

9.  Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy.

Authors:  Mary Jane Minkin; Ricardo Maamari; Suzanne Reiter
Journal:  Int J Womens Health       Date:  2014-03-12

Review 10.  Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.

Authors:  Rossella E Nappi; Nicoletta Biglia; Angelo Cagnacci; Costantino Di Carlo; Stefano Luisi; Anna Maria Paoletti
Journal:  Gynecol Endocrinol       Date:  2016-05-17       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.